Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Vermont Wants Drugmakers To Be Held Accountable For Pharmaceutical Price Increases

XTALKS VITALS NEWS

Drug Pricing

Vermont is currently the first state to successfully pass such a transparency bill through both Legislative houses.

Share this!

May 17, 2016 | by Sarah Massey, M.Sc.

In Vermont, a new bill is on the table which could require pharmaceutical companies to explain their reasoning behind price increases of prescription drugs. Drug pricing has been a hot topic lately, with Valeant and Turing’s price increases pushing the issue into the media spotlight.

While drugmakers often cite the research and development costs related to developing a new drug as the reason for high list prices, others point to gaps in the federal government’s ability to negotiate better pricing. Christopher Pearson, a Vermont state representative and a member of the Vermont Progressive Party from the state's largest city, Burlington, is a strong supporter of the proposed legislation.

Prescription drugs are often much less expensive in other countries outside the US, Pearson points out. According to him, Medicare and Medicaid have little bargaining power when it comes to getting the best price for pharmaceuticals.

Vermont is currently the first state to successfully pass such a transparency bill through both Legislative houses, according to Priscilla VanderVeer, spokeswoman for the Pharmaceutical Research and Manufacturers of America (PhRMA). Other states, including Pennsylvania, Massachusetts, New York, Virginia and California, have all had drug pricing bills under consideration since 2015.



The proposed Vermont bill would require state healthcare regulators to compose an annual list of up to 15 drugs whose prices have been increased. The drugmakers would then have to justify their price increases to the state’s attorney general’s office.

In a statement, VanderVeer said Vermont’s legislation was misguided, and that drugs actually help patients avoid hospitalizations and expensive procedures, thereby helping to control healthcare spending. “Instead of passing legislation that makes a political point, we believe the Legislature should have focused instead on giving patients and families what they actually need: predictable and accessible information about the out-of-pocket costs they will face and enforceable, common-sense rules ... that remove barriers to receiving care,” said VanderVeer.

Representative Peter Welch, a Democrat and Vermont's only congressman, is in support of the bill, especially since Congress has been slow to act on reining-in prescription drug pricing. “Why can't the state say to the pharmaceutical companies selling the drug, ‘Hey, if you're going to hammer us with a 50 percent price increase, we want to know why’?”


Keywords: Drug Pricing, Pharmaceutical Industry, American Politics


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News


FDA Approves New Drug for Parkinson’s Disease

March 23, 2017 - Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease.

Featured In: Clinical Trials News, Life Science News, Pharmaceutical News


Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.